Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A830 · 1 trial · 1 indication
Number of Participants With of DLTs
The number of participants with Adverse Events and Treatment-Related Adverse Events as Assessed by CTCAE v6.0
Assessed by investigators according to RECIST 1.1
The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.
| Arm | Type | Description |
|---|---|---|
| Part A (Dose Escalation) | EXPERIMENTAL | - |
| Part B (Dose Optimization) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| HMPL-A830 | DRUG | Enrolled participants with solid tumors will receive HMPL-A830 treatment in a dose escalation setting at 6 predefined dose levels |
Inclusion Criteria: 1. Understood this study and are able to voluntarily sign the informed consent form (ICF); 2. Male or Female, Age ≥ 18 years; 3. Histological confirmed, unresectable, advanced or metastatic solid tumor 4. Participants must have at least one measurable lesion per Response Evaluat...
HMPL-A830 is an investigational small molecule being developed for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in patients with advanced solid tumors.
HMPL-A830 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM. The company is conducting clinical trials for this investigational oncology drug.
HMPL-A830 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being evaluated for safety and efficacy in clinical trials.
HMPL-A830 is being studied in a Phase 1 clinical trial registered as NCT07718581, titled "HMPL-A830 in Solid Tumors." The trial is planned to enroll 147 adult patients with solid tumors and is being conducted in China. The study is not yet recruiting participants.
No, the Phase 1 clinical trial of HMPL-A830 is not randomized and is not double-blind. It is a controlled study, meaning there is a control group, but the trial design does not involve randomization or blinding of the treatment assignment.
Yes, the Phase 1 clinical trial of HMPL-A830 uses biomarker-selected patient enrollment. This means that patients are chosen for the study based on the presence of specific biomarkers, which may help identify those most likely to benefit from the treatment.